The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ATHA | +23.68% | -97.52% | -52.27% | -96% |
| S&P | +18.55% | +83.81% | +12.95% | +109% |
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$243.00K | 0.0% |
| Market Cap | $16.33M | -5.3% |
| Market Cap / Employee | $628.00K | 0.0% |
| Employees | 26 | 0.0% |
| Net Income | -$6,611.00K | 77.0% |
| EBITDA | -$6,631.00K | 73.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.87M | -73.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $460.00K | -49.6% |
| Short Term Debt | $452.00K | 12.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -64.88% | 15.7% |
| Return On Invested Capital | -73.32% | -134.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,668.00K | 79.7% |
| Operating Free Cash Flow | -$4,668.00K | 79.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.51 | 0.30 | 0.37 | 0.51 | 70.45% |
| Price to Tangible Book Value | 3.94 | 2.48 | 3.16 | 0.51 | -75.18% |
| Enterprise Value to EBITDA | 1.78 | 2.63 | 2.40 | 1.20 | -48.22% |
| Return on Equity | -110.8% | -110.7% | -103.8% | -89.4% | -13.07% |
| Total Debt | $1.22M | $1.12M | $1.02M | $912.00K | -30.59% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
